Nonpharmacologic approaches for the treatment of hyperlipidemia.

Abstract

Coronary heart disease (CHD) is the leading cause of death in the United States. Dyslipidemias, like decreased high-density lipoprotein (HDL) and increased low-density lipoprotein (LDL), have been linked through epidemiologic and experimental studies with the development of atherosclerosis and an increased risk of CHD. The introduction of various classes of lipid-lowering drugs, especially the hydroxymethylglutaryl-coenzyme-A-reductase inhibitors (statins), has allowed for effective treatment of hyperlipidemia. This article reviews the following nonpharmacologic approaches to hyperlipidemia: LDL apheresis, surgery, the emergence of HDL as a therapeutic target, gene therapy, and finally, the possibility of developing a vaccine against atherosclerosis.

• Authors: Tanaz Kermani, William H Frishman
• Journal: Cardiology in review (Cardiol Rev) 2005 Sep-Oct Vol. 13 Issue 5 Pg. 247-55 ISSN: 1061-5377 [Print] United States
• PMID: 16106186 (Publication Type: Journal Article, Review)

Chemical References

• Apolipoprotein A-I
• Autoantigens
• Cholesterol, HDL
• Cholesterol, LDL

Topics

• Apolipoprotein A-I (administration & dosage, genetics)
• Autoantigens (administration & dosage)
• Blood Component Removal
• Cholesterol, HDL (administration & dosage)
• Cholesterol, LDL (blood)
• Clinical Trials as Topic
• Genetic Therapy
• Humans
• Hyperlipidemias (complications, immunology, therapy)
• Hyperlipoproteinemia Type II (therapy)
• Ileum (surgery)
• Treatment Outcome
• Vaccination